Bristol CEO Giovanni Caforio, AP

Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long lives

Bris­tol My­ers Squibb has seen set­back af­ter set­back for its chances to bring im­muno-on­col­o­gy block­buster Op­di­vo in­to new­ly di­ag­nosed brain can­cer pa­tients — a sort …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.